NCT06986174 is a Phase 2 clinical trial of Pacritinib in Waldenström Macroglobulinemia, sponsored by Shayna Sarosiek, MD.

Who is sponsoring NCT06986174?

NCT06986174 is sponsored by Shayna Sarosiek, MD.

What drugs are being tested in NCT06986174?

Interventions in NCT06986174: Pacritinib.

What condition does NCT06986174 study?

NCT06986174 studies Waldenström Macroglobulinemia, Lymphoplasmacytic Lymphoma, B-Cell Lymphoproliferative Disorder, Indolent Lymphoma.

Is NCT06986174 still recruiting?

NCT06986174 is currently recruiting now. Last updated 5 December 2025.

Last reviewed 2025-12-05 · How we verify

NCT06986174

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Phase 2 Study to Evaluate the Safety and Efficacy of Pacritinib in Relapsed or Refractory Waldenström Macroglobulinemia

Recruiting now Phase 2 Last updated 5 December 2025

What this trial tests

Phase 2 trial testing Pacritinib in Waldenström Macroglobulinemia in 30 participants. Currently enrolling.

Timeline

21 November 2025

Primary endpoint
1 October 2028

1 October 2032

Quick facts

Lead sponsor	Shayna Sarosiek, MD
Phase	Phase 2
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	30
Start date	21 November 2025
Primary completion	1 October 2028
Estimated completion	1 October 2032
Sites	1 location across United States

Drugs / interventions tested

Pacritinib (PACRITINIB) — full drug profile →

Conditions studied

Waldenström Macroglobulinemia — all drugs for Waldenström Macroglobulinemia →
Lymphoplasmacytic Lymphoma — all drugs for Lymphoplasmacytic Lymphoma →
B-Cell Lymphoproliferative Disorder — all drugs for B-Cell Lymphoproliferative Disorder →
Indolent Lymphoma — all drugs for Indolent Lymphoma →

Sponsor

Shayna Sarosiek, MD

Who can join

18 and older, any sex, with Waldenström Macroglobulinemia or Lymphoplasmacytic Lymphoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study is being done to examine the safety and effectiveness of pacritinib as a possible treatment for participants with Waldenström macroglobulinemia (WM). The name of the study drug involved in this study is: -Pacritinib (a type of kinase inhibitor)

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Repurposing pacritinib to target MYD88-mutated Waldenström macroglobulinaemia.
Liu S, Kofides A, Liu X, Hatcher JM, et al · · 2026 · PMID 41255253 · DOI 10.1111/bjh.70254

Verify or expand the search:

Other trials of Pacritinib

Trials testing the same drug.

NCT06675123 — Pacritinib in Combination With a BTK Inhibitor for the Treatment of Patients With Relapsed or Refractory Mantle Cell Lym · Phase 1 · recruiting
NCT07447817 — Selinexor and Pacritinib in JAK Inhibitor-naïve MF Patients With Cytopenias · Phase 2 · not yet recruiting
NCT07148947 — Pacritinib With Standard of Care Azacitidine or Decitabine as a Bridge to Allogeneic Hematopoietic Stem Cell Transplant · Phase 2 · recruiting
NCT07226713 — Pacritinib in Participants With Metastatic Castrate-Resistant Prostate Cancer That Progressed on or After Prior Treatmen · Phase 2 · not yet recruiting
NCT06782373 — A Study to Assess the Effectiveness and Safety of Pacritinib in Patients With VEXAS Syndrome (PAXIS) · Phase 2 · recruiting

Other recruiting trials for Waldenström Macroglobulinemia

Currently open trials in the same condition.

NCT05294731 — Treatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein-Deg · Phase 1, PHASE2 · recruiting
NCT01815749 — Genetically Modified T-cell Infusion Following Peripheral Blood Stem Cell Transplant in Treating Patients With Recurrent · Phase 1 · active not recruiting

Other Shayna Sarosiek, MD trials

Trials by the same sponsor.

NCT05190705 — Loncastuximab Tesirine in WM · Phase 2 · recruiting
NCT05065554 — ACALA-R In Predominantly Demyelinating IgM Mediated Neuropathy · Phase 2 · active not recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06986174 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Shayna Sarosiek, MD
Last refreshed: 5 December 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06986174.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing